Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Background Available data show that COVID-19 vaccines may be less effective in immunocompromised populations, who are at increased risk of severe COVID-19. Objectives We conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations. Data sources We searched Medline and Embase databases. Study eligibility criteria, patients, interventions We included studies of COVID-19 vaccines after complete vaccination in immunocompromised patients until 31 August 2021. Studies with <10 patients, safety data only and case series of breakthrough infections were excluded. Methods Risk of bias was assessed via the tool developed by the National Institutes of Health on interventional and observational studies. Immunogenicity was assessed through non-response rate defined as no anti-SARS-CoV-2 spike protein antibodies, efficacy and effectiveness by the relative reduction in risk of SARS-CoV-2 infection or COVID-19. We collected factors associated with the risk of non-response. We presented collected data by immunosuppression type. Results We screened 5917 results, included 162 studies. There were 157 on immunogenicity in 25 209 participants, including 7835 cancer or haematological malignancy patients (31.1%), 6302 patients on dialysis (25.0%), 5974 solid organ transplant recipients (23.7%) and 4680 immune-mediated disease patients (18.6%). Proportion of non-responders seemed higher among solid organ transplant recipients (range 18–100%) and patients with haematological malignancy (range 14–61%), and lower in patients with cancer (range 2–36%) and patients on dialysis (range 2–30%). Risk factors for non-response included older age, use of corticosteroids, immunosuppressive or anti-CD20 agent. Ten studies evaluated immunogenicity of an additional dose. Five studies evaluated vaccine efficacy or effectiveness: three on SARS-CoV-2 infection (range 71–81%), one on COVID-19-related hospitalization (62.9%), one had a too small sample size. Conclusions This systematic review highlights the risk of low immunogenicity of COVID-19 vaccines in immunocompromised populations, especially solid organ transplant recipients and patients with haematological malignancy. Despite lack of vaccine effectiveness data, enhanced vaccine regimens may be necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · cited 2×
“Risk factors for non-response status often included older age, which is consistent with data provided by phase 1 and 2 studies of COVID-19 vaccines [191,192], as well as in other vaccines such as influenza, pneumococcal and hepatitis B vaccines [202e205].”
BackgroundResultBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“Estimates of effectiveness appear lower than in the general population [183,213,214], which is consistent with the findings of this review regarding a diminished immunogenicity and reports of more breakthrough infections observed in these populations [215e217].”
ResultFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564 · cited 1×
“Estimates of effectiveness appear lower than in the general population [183,213,214], which is consistent with the findings of this review regarding a diminished immunogenicity and reports of more breakthrough infections observed in these populations [215e217].”
ResultInterim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034201 · Cited by 1,208
Antibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103055 · Cited by 625
Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · doi:10.1101/2021.02.25.21252477 · Cited by 625
Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01449-9 · Cited by 425
Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., Mandelboim, M., Doolman, R., Amit, S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00220-4 · Cited by 342
Hua, C., Barnetche, T., Combe, B., & Morel, J. (2014) · Arthritis Care & Research · doi:10.1002/acr.22246 · Cited by 287
Spiera, R., Jinich, S., & Jannat-Khah, D. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220604 · Cited by 180
The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
Chodick, G., Tene, L., Rotem, R. S., Patalon, T., Gazit, S., Ben-Tov, A., Weil, C., Goldshtein, I., Twig, G., Cohen, D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab438 · Cited by 176 · cited 3×
“which took place during periods of high local prevalence of the alpha variant [183].”
BackgroundResultRondaan, C., Furer, V., Heijstek, M. W., Agmon-Levin, N., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., van Laar, J. M., et al. (2019) · RMD Open · doi:10.1136/rmdopen-2019-001035 · Cited by 154
Marion, O., Del Bello, A., Abravanel, F., Couat, C., Faguer, S., Esposito, L., Hebral, A. L., Izopet, J., & Kamar, N. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1341 · Cited by 142
Cancer associates with risk and severe events of COVID ‐19: A systematic review and meta‐analysis
Tian, Y., Qiu, X., Wang, C., Zhao, J., Jiang, X., Niu, W., Huang, J., & Zhang, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33213 · Cited by 129 · cited 1×
“However, these large-scale premarketing studies provide little information on vaccine efficacy in immunocompromised populations, while current evidence shows an increased risk of severe COVID-19 inpatientswith cancer [1], solid organ transplant [2,3], end-stage renal disease [4,5] and rheumatic immune-mediated disease…”
BackgroundRituximab-treated patients have a poor response to influenza vaccination
Eisenberg, R. A., Jawad, A. F., Boyer, J., Maurer, K., McDonald, K., Prak, E. T. L., & Sullivan, K. E. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9813-x · Cited by 126 · cited 1×
“These reports are consistent with immune response to other vaccines in populations receiving such treatments, mycophenolate [194] and anti-CD20 agents (in a rheumatological indication [206,207], haematological malignancy [208,209] or multiple sclerosis [210]), methotrexate [211], while TNF inhibitors variously affect…”
ResultBNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
Peled, Y., Ram, E., Lavee, J., Sternik, L., Segev, A., Wieder-Finesod, A., Mandelboim, M., Indenbaum, V., Levy, I., Raanani, E., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.003 · Cited by 126 · cited 2×
“Eleven studies reported results of neutralization assays [34,63,66,69,72,77,79,126,145].”
BackgroundResultLustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., Mandelboim, M., Doolman, R., Amit, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3790408 · Cited by 4
Cited by
Marzano, P., Balin, S., Terzoli, S., Della Bella, S., Cazzetta, V., Piazza, R., Sandrock, I., Ravens, S., Tan, L., Prinz, I., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1208662 · Cited by 13
Metadata
- Authors
- Galmiche, S., Luong Nguyen, L. B., Tartour, E., de Lamballerie, X., Wittkop, L., Loubet, P., & Launay, O.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 28
- Issue
- 2
- Pages
- 163-177
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W3212101057
- Cited by
- 205
- References
- 24
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.